论文部分内容阅读
[目的]探讨C8092A、-673C>T单核苷酸多态性对顺铂为基础化疗非小细胞肺癌(NSCLC)患者疗效的影响。[方法]采用多聚酶链反应—限制片段长度多态性(PCR-RFLP)法对NSCLC患者进行基因分型,并分析基因多态性与化疗疗效的相关性。[结果]C8092A野生型(CC)与携带A等位基因(CA+AA)客观有效率无统计学差异(24.1%vs25.0%,P>0.05),野生型的疾病控制率与携带A等位基因差异无统计学意义(82.8%vs68.8%,P>0.05);野生型无进展生存期(PFS)223.8d,携带A等位基因者219.5d(P>0.05)。-673C>T野生型(CC)与携带T等位基因型(CT+TT)客观有效率无统计学差异(25.0%vs23.8%,P>0.05);携带T等位基因疾病控制率与野生型患者差异无统计学意义(81.0%vs72.5%,P>0.05);野生型PFS221.4d,携带T等位基因型PFS233.5d(P>0.05)。[结论]以顺铂为基础化疗NSCLC患者疗效与C8092A、-673C>T单核苷酸多态性(SNP)无关。
[Objective] To investigate the effect of C8092A, -673C> T SNPs on the efficacy of cisplatin-based chemotherapy in patients with non-small cell lung cancer (NSCLC). [Methods] The genotypes of patients with NSCLC were genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and the correlation between gene polymorphism and chemotherapy efficacy was analyzed. [Results] The objective efficiency of C8092A wild type (CC) and carrying A allele (CA + AA) had no statistical difference (24.1% vs 25.0%, P> 0.05) (82.8% vs68.8%, P> 0.05). The progression-free survival (PFS) of wild type was 223.8 days, and that of the A allele was 219.5 days (P> 0.05). -673C> There was no significant difference in the objective efficiency of T allele (CT + TT) compared with that of T allele (25.0% vs23.8%, P> 0.05) There was no significant difference in the wild type patients (81.0% vs72.5%, P> 0.05). The wild type PFS221.4d and T allele PFS233.5d (P> 0.05). [Conclusion] The efficacy of Cisplatin-based chemotherapy in patients with NSCLC has nothing to do with C8092A, -673C> T single nucleotide polymorphism (SNP).